Mar­ket­ingRx roundup: Phar­mas nab ‘green­est’ awards; Gilead spon­sors ESG ex­ec­u­tive con­fer­ence

Last year
Pharma
Marketing

Bris­tol My­ers notch­es di­ver­si­ty gains af­ter re­vamp­ing its clin­i­cal tri­al lo­ca­tion strat­e­gy

Last year
Pharma
Marketing

Re­gen­eron ex­pands CRISPR deal with In­tel­lia; Cap­si­da, Kate's gene ther­a­py man­u­fac­tur­ing deal; Bio­haven’s $225M ...

Last year
News Briefing

Bridge­Bio part­ners with bio­man­u­fac­tur­er Re­silience to pro­duce ear­ly-stage AAV gene ther­a­pies

Last year
R&D
Manufacturing

AI-dri­ven biotech Iambic snags $100M to en­ter the clin­ic next year in HER2 field

Last year
Financing
Startups

Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

Last year
R&D
AI

The End­points Slack in­ter­view: Celli­no CEO Nabi­ha Sak­layen on cell ther­a­py's fu­ture, Elon Musk and time trav­el

Last year
People
Startups

Phar­ma­cy op­er­a­tions start­up Plen­ful rais­es $9M

Last year
Health Tech

Up­dat­ed: In turn­around, ALX On­col­o­gy’s CD47 block­er shows ef­fi­ca­cy in gas­tric can­cer tri­al

Last year
R&D

Eli Lil­ly to buy ra­dio­phar­ma com­pa­ny Point Bio­phar­ma for $1.4B as PhI­II read­out looms

Last year
Deals
Pharma

As­traZeneca pays out $425M to set­tle lit­i­ga­tion over Prilosec and Nex­i­um but ad­mits no wrong­do­ing

Last year
Pharma
Law

Sanofi slides J&J’s E. coli vac­cine in­to late-stage port­fo­lio, bet­ting $175M cash on de­vel­op­ment, com­mer­cial­iza­tion ...

Last year
Deals

FDA re­jects Gal­der­ma’s liq­uid neu­ro­tox­in due to CMC is­sues 

Last year
FDA+
Manufacturing

Take­da to pull lung can­cer drug Exkiv­i­ty world­wide af­ter con­fir­ma­to­ry tri­al dis­ap­point­ment

Last year
Pharma

I'll be in Lon­don next week with the End­points crew and a great line­up of biotech ex­perts and in­sid­ers. Join us

Last year
Bioregnum

Health tech fund­ing lev­els out as star­tups raise $2.5B in third quar­ter

Last year
Startups
Health Tech

Hori­zon de­buts lat­est thy­roid eye dis­ease TV com­mer­cials as Am­gen merg­er nears

Last year
Pharma
Marketing

No­vo Nordisk se­cures FDA ap­proval of RNAi ther­a­py from $3.3B Dicer­na takeover

Last year
Pharma
FDA+

Flag­ship poach­es an­oth­er phar­ma R&D leader as GSK's Lep­ore heads to Pro­Found

Last year
People
Startups

Bio­gen nabs FDA ap­proval for its biosim­i­lar of arthri­tis and Covid-19 drug Actem­ra

Last year
Pharma
FDA+

Fed­er­al judge de­nies Cham­ber of Com­merce's ef­fort to block IRA's Medicare drug price ne­go­ti­a­tion pro­vi­sions

Last year
Pharma
FDA+

All phar­ma com­pa­nies in the first round of Medicare price ne­go­ti­a­tions agree to par­tic­i­pate

Last year
Pharma

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II

Last year
News Briefing

No­var­tis to seek ac­cel­er­at­ed ap­proval for oral com­ple­ment in­hibitor in rare kid­ney dis­ease

Last year
R&D
FDA+
First page Previous page 270271272273274275276 Next page Last page
A service from the Financial Times